Your browser doesn't support javascript.
loading
Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study.
Hoxha, Ariela; Perin, Nicola; Lovisotto, Marco; Calligaro, Antonia; Del Ross, Teresa; Favaro, Maria; Tonello, Marta; Doria, Andrea; Simioni, Paolo.
Afiliação
  • Hoxha A; Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine, University of Padua, Italy. Electronic address: ariela.hoxha@unipd.it.
  • Perin N; Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine, University of Padua, Italy.
  • Lovisotto M; Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine, University of Padua, Italy.
  • Calligaro A; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Del Ross T; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Favaro M; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Tonello M; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Doria A; Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
  • Simioni P; Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine, University of Padua, Italy.
J Autoimmun ; 144: 103180, 2024 04.
Article em En | MEDLINE | ID: mdl-38368768
ABSTRACT

BACKGROUND:

Despite anticoagulant therapy, a antiphospholipid syndrome (APS) has a higher rate of recurrent events, which can lead to damage accrual and a negative impact on life quality.

OBJECTIVES:

To evaluate the risk factors and APS subsets associated with damage accrual. PATIENTS/

METHODS:

We conducted a retrospective single-center study. We reviewed the medical records of 282 APS patients, with a median age of 36 (IQR 30-46) years and a median of 195 (IQR 137-272) months. The primary endpoint was damage accrual during follow-up, defined as organ/tissue impairment present for at least six months or causing permanent loss. The secondary endpoints were early organ damage within six months of disease onset and death.

RESULTS:

Eighty (28.4%) patients presented damage accrual; 52.5% developed damage within six months of APS onset, and 41.3% had more than one organ involved. Neuropsychiatric involvement, affecting 38.8% of the patients, was the most frequent, followed by peripheral vasculopathy and renal involvement, 35% either. Death happened in 7 (2.5 %) patients; damage accrual was associated with a 6-fold risk of death [OR 6.7 (95% CI 1.3-35.1), p = 0.03]. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual with 5-fold and 4-fold higher risk, respectively [(OR 4.9 (95% CI 2.1-11.7), p < 0.0001 and (OR 3.8 (95% CI 1.5-10.1), p = 0.007]. The cumulative incidence of damage accrual increased by 5.7-fold and 3.6-fold in patients with microangiopathy and non-criteria manifestations.

CONCLUSIONS:

APS patients had a higher frequency of damage accrual. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Antifosfolipídica / Lúpus Eritematoso Sistêmico Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Antifosfolipídica / Lúpus Eritematoso Sistêmico Idioma: En Ano de publicação: 2024 Tipo de documento: Article